Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 6-7, Juin-Juillet 2004
Page(s) 643 - 650
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004206-7643
Publié en ligne 15 juin 2004
  1. Korup E, Dalsgaard D, Nyvad O, et al. Comparison of degrees of left ventricular dilation within three hours and up to six days after onset of first acute myocardial infarction. Am J Cardiol 1997; 80 : 449–53
  2. Seals AA, Pratt CM, Mahmarian JJ, et al. Relation of left ventricular dilation during acute myocardial infarction to systolic performance, diastolic dysfunction, infarct size and location. Am J Cardiol 1988; 61 : 224–9.
  3. de Kam PJ, Nicolosi GL, Voors AA, et al. Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. Eur Heart J 2002; 23 : 536–42.
  4. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76 : 44–51.
  5. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium : Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26 : 279–92.
  6. Gao XM, Dart AM, Dewar E, et al. Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc Res 2000; 45 : 330–8.
  7. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991; 260 : H1406–14.
  8. Sugden PH. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 2003; 93 : 1179–92.
  9. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy : Where have we been ? Where are we going ? J Physiol (Lond) 2002; 541 : 1–8.
  10. Knöll R, Hoshijima M, Hoffmann HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 2002; 111 : 943–55.
  11. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1998; 274 : 21491–4.
  12. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999; 5 : 1135–42.
  13. Lindsey M, Wedin K, Brown MD, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001; 103 : 2181–7.
  14. Etoh T, Joffs C, Deschamps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001; 281 : H987–94.
  15. Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285 : H1229–35.
  16. Lijnen H. R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86 : 324–33.
  17. Creemers E, Cleutjens J, Smits J, et al. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 2000; 156 : 1865–73.
  18. Rahkonen OP, Koskivirta IM, Oksjoki SM, et al. Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA. Biochim Biophys Acta 2002; 1577 : 45–52.
  19. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27 : 1281–92.
  20. Tyagi SC, Kumar SG, Haas SJ, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 1996; 28 : 1415–28.
  21. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000; 46 : 307–15.
  22. Sun Y, Zhang JQ, Zhang J, Lamparter S. Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 2000; 135 : 316–23.
  23. Li YY, Feldman AM, Sun Y, McTierman CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998; 98 : 1728–34.
  24. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000; 102 : 1944–9.
  25. Romanic AM, Burns-Kurtis CL, Gout B, et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 2001; 68 : 799–814.
  26. Fedak PW, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure : A possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 2003; 284 : H626–34.
  27. Zimmerman SD, Thomas DP, Velleman SG, et al. Time course of collagen and decorin changes in rat cardiac and skeletal muscle post-MI. Am J Physiol Heart Circ Physiol 2001; 281 : H1816–22.
  28. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89 : 151–63.
  29. Hochman JS, Choo H. Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 1987; 75 : 299–306.
  30. Chareonthaitawee P, Christian TF, Hirose K, et al. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. J Am Coll Cardiol 1995; 25 : 567–73.
  31. Lange RA, Hillis LD. Reperfusion therapy in acute myocardial infarction. N Engl J Med 2002; 346 : 954–5.
  32. Kloner RA. Does reperfusion injury exist in humans ? J Am Coll Cardiol 1993; 21 : 537–45.
  33. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85 : 1699–705.
  34. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the ’no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93 : 223–8.
  35. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97 : 765–72.
  36. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000; 101 : 2734–41.
  37. GISSI-3 trial. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction : The GISSI-3 trial. Gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico. J Am Coll Cardiol 1996; 27 : 337–44.
  38. ISIS-4 (Fourth International study of infarct survival) Collaborative Group. ISIS-4 : A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345 : 669–85.
  39. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92 : 3132–7.
  40. Rouleau JL, de Champlain J, Klein M, et al. Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol 1993; 22 : 390–8.
  41. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts : Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26 : 809–20.
  42. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure : Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102 : 2700–6.
  43. Pitt B, Remme W, Zannad F, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 : 1309–21.
  44. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107 : 2559–65.
  45. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure : Effects on left ventricular dimensions and function. Circ Res 1999; 85 : 364–76.
  46. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003; 107 : 618–25.
  47. Yarbrough WM, Mukherjee R, Escobar GP, et al. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 2003; 108 : 1753–9.
  48. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357 : 279–80.
  49. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106 : 1913–8.
  50. Assmus B, Schachinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106 : 3009–17

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.